 SOUTH SAN FRANCISCO, Calif., June 07, 2022 GLOBE NEWSWIRE -- Lyell Immunopharma, Inc., Nasdaq: LYEL, a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 at 10:40am PT. 